Evaluation of the Reasons and Consequences of Bleeding in Late Teens and Early Adulthood Patients With Severe Hemophilia A

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Hematologic DiseaseBlood Coagulation Disorders
Interventions
BEHAVIORAL

Recombinant Factor VIII (Kogenate, BAY 14-2222)

Subjects electing to stay on the prophylactic treatment (prospective)

BEHAVIORAL

Recombinant Factor VIII (Kogenate, BAY 14-2222)

Subjects electing to switch to on-demand treatment (prospective)

BEHAVIORAL

Recombinant Factor VIII (Kogenate, BAY 14-2222)

Subjects remaining on-demand treatment (retrospective)

Trial Locations (10)

61614

Peoria

65109

Jefferson City

76104

Fort Worth

77030

Houston

80262

Denver

89109

Las Vegas

91010

Duarte

Unknown

Many Locations

Many Locations

Many Locations

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY